Metabiomics

Founded in 2010, Metabiomics is a private diagnostics company pioneering the use of the gut microbiome for disease detection and health assessment. Its core technology platform analyzes stool samples to identify specific microbial DNA markers associated with gastrointestinal pathologies, aiming to offer alternatives to invasive procedures like colonoscopies. The company appears to be in a late-development or early-commercial stage with its lead test for colorectal cancer screening. Its success hinges on clinical validation, market adoption against established screening methods, and navigating the complex reimbursement landscape for novel diagnostics.

Proprietary platform analyzing microbial DNA signatures from stool samples to detect and monitor gastrointestinal diseases.

Metabiomics competes in the non-invasive CRC screening market against dominant players like Exact Sciences (Cologuard) and traditional FIT tests. It also faces competition from other microbiome diagnostic startups (e.g., Viome, DayTwo) and large diagnostic firms (e.g., Quest, LabCorp) developing similar technologies. Differentiation hinges on superior accuracy, convenience, and cost.